Ticker Symbol: TOS/TSX
Shares Outstanding: 47,863,402
QUEBEC CITY, Feb. 5 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announces the signing of an agreement with Broadlane, a leading supply chain
services company that provides technology-oriented business solutions to
improve the financial and operational performance of thousands of acute care
hospitals, ambulatory care facilities, physician practices and other
healthcare providers throughout the United States. This new multi-year
contract effective Feb. 1, 2008, offers exclusive pricing and price protection
to Broadlane clients on the 125L Ozone Sterilizer, and all TSO3 Service and
"TSO3 is very proud of having been chosen by Broadlane's clients as a
partner and given the opportunity to present its product to the many hospitals
Broadlane serves," said Jocelyn Vézina, CEO at TSO3. "We fully intend to take
advantage of this opportunity to further penetrate the U.S. market."
Broadlane's services focus on the supply chain, clinical workforce
management and high-cost clinical areas. These solutions are supported by a
suite of proprietary Web-based technologies and tools delivered on an ASP
(Application Service Provider) basis, account management, implementation and
outsourcing services and informatics.
"Broadlane clients asked us to contract with TSO3 on their behalf, and as
a result, we are the first GPO (Group Purchasing Organization) to enter into a
contract with TSO3," said Michael Berryhill, Executive Vice President, Supply
Chain Services, Broadlane.
"Based on my past experience in the industry, agreements like this are an
important addition to the sales efforts of a company," said Jim Mazzarella,
Director of National Accounts for TSO3. "We believe Broadlane's clients will
be more comfortable purchasing our new technology because they made the
More about Broadlane
Broadlane provides comprehensive supply chain services including:
- High-powered national & custom contracting
- Innovative Procurement Services & technology
- Informatics - benchmarking, analytics and reporting
- Deep clinical & operational expertise
- High-touch client service
Broadlane's clients include leading providers such as Advocate Health
Care, Ascension Health, CHRISTUS Health, Continuum Health Partners, Kaiser
Permanente, Kindred Healthcare, MedCath Corporation, New Hanover Regional
Medical Center, Tenet Healthcare, The Health Alliance of Greater Cincinnati,
Universal Health Services, US Oncology, Sisters of Charity of Leavenworth
Health System, St. Luke's Episcopal Health System, UMass Memorial Health Care
and William Beaumont Hospitals.
The company is headquartered in Dallas with offices in California, New
York and Ohio. For more information, visit www.broadlane.com
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology with high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
TSO3 currently has more than 72 employees, about half of whom work in the
sales and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Caroline Côté, Director, Corporate
Communications & IR, (418) 651-0003, Ext. 237, firstname.lastname@example.org; Source: TSO(3)